{"id":294263,"date":"2024-06-26T00:00:00","date_gmt":"2024-06-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0015-2024-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment\/"},"modified":"2026-03-31T10:29:24","modified_gmt":"2026-03-31T10:29:24","slug":"cutrcg0015-2024-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment-physician-insights","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0015-2024-biopharma-major-depressive-disorder-dsm-v-current-treatment-current-treatment-physician-insights\/","title":{"rendered":"Major Depressive Disorder (DSM-V) &#8211; Current Treatment &#8211; Current Treatment: Physician Insights \u2013 Major Depressive Disorder (EU5)"},"content":{"rendered":"<p>Agents for treating major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) span multiple drug classes; while selective serotonin reuptake inhibitors (<abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s) and serotonin \/ norepinephrine reuptake inhibitors (<abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s) are considered the standards of care, branded therapies, including Brintellix (Lundbeck\u2019s vortioxetine) and Spravato (Johnson &#038; Johnson Innovative Medicine\u2019s esketamine), are important treatment alternatives, particularly for treatment-resistant depression (<abbr title=\"treatment-resistant depression\">TRD<\/abbr>). Given the highly genericized nature of the <abbr title=\"major depressive disorder\">MDD<\/abbr> therapy market, the differences in the availability of drugs in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, the heterogeneity of the <abbr title=\"major depressive disorder\">MDD<\/abbr> patient population, and patients\u2019 varied responses to treatment, the prescribing pattern of <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> psychiatrists and <abbr title=\"general practitioner\">GP<\/abbr>s \/ internists can vary. Understanding the decision points and challenges that physicians face when treating <abbr title=\"major depressive disorder\">MDD<\/abbr> is paramount for marketers of current therapies and developers of emerging therapies to assess the opportunities for drug development in this highly prevalent indication in Europe.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers and constraints influencing physicians\u2019 treatment decisions for <abbr title=\"major depressive disorder\">MDD<\/abbr>?<\/li>\n<li>How are patients being treated in various lines of therapy, and what is the patient share of individual therapies?<\/li>\n<li>What percentage of drug-treated <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are partial responders, and what percentage are treatment-resistant? What is the most common course of action for partial responders and <abbr title=\"treatment-resistant depression\">TRD<\/abbr> patients?<\/li>\n<li>What drives switching to and from key brands (e.g., Brintellix, Spravato)?<\/li>\n<li>To what extent is polypharmacy used for <abbr title=\"major depressive disorder\">MDD<\/abbr> in different lines of therapy in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> (France, Germany, Italy, Spain, and the United Kingdom).<\/p>\n<p><strong>Key companies:<\/strong> Johnson &#038; Johnson Innovative Medicine, Lundbeck, Otsuka, Gedeon Richter, Recordati.<\/p>\n<p><strong>Key drugs:<\/strong> Brintellix, Spravato, Reagila, Rxulti, <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s, <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 127 <abbr title=\"general practitioner\">GP<\/abbr>s\/internists and 125 psychiatrists<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage or treatment approach<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-294263","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-psychiatry","biopharma-product-current-treatment","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263\/revisions"}],"predecessor-version":[{"id":575943,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294263\/revisions\/575943"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}